

In the Claims

1.-12. (Cancelled)

13. (Currently Amended) A method of decreasing intratumoral vessels to inhibit growth of melanoma and pulmonary metastases in a mammal comprising:

administering by electrotransfer to an intramuscular site or an intratumoral site in the mammal a therapeutically effective amount of a nucleic acid molecule comprising an expression plasmid coding for the disintegrin domain encoded by a polynucleotide consisting of the polynucleotide sequence shown in SEQ ID NO: 1 where SEQ ID NO: 1 is operably linked to a promoter or expression control sequence.

14.-15. (Cancelled)

16. (Currently Amended) The method according to claim [[15]] 13, wherein the disintegrin domain is Met-1 to Glu-91 shown in SEQ ID NO: 2.

17. (Currently Amended) A method of treating melanoma in a mammal comprising decreasing intratumoral vessels to inhibit growth of the melanoma by administering via electrotransfer to an intramuscular site or an intratumoral site in the mammal a therapeutically effective amount of a nucleic acid molecule comprising an expression plasmid coding for the disintegrin domain encoded by a polynucleotide consisting of the polynucleotide sequence shown in SEQ ID NO: 1 where SEQ ID NO: 1 is operably linked to a promoter or expression control sequence.

18.-19. (Cancelled)

20. (Currently Amended) A method according to claim [[19]] 17, wherein the disintegrin domain is Met-1 to Glu-91 shown in SEQ ID NO: 2.

21. (Currently Amended) A method of treating pulmonary metastases in a mammal comprising inhibiting the metastases by decreasing intratumoral vessels by administering via electrotransfer to an intramuscular site or an intratumoral site in the mammal a therapeutically effective amount of a nucleic acid molecule comprising an expression plasmid coding for the disintegrin domain encoded by a polynucleotide consisting of the polynucleotide sequence shown in SEQ ID NO: 1 where SEQ ID NO: 1 is operably linked to a promoter or expression control sequence.

22. (Cancelled)

23. (Currently Amended) The method according to claim [[24]] 21, wherein the disintegrin domain is Met-1 to Glu-91 shown in SEQ ID NO: 2.

24. (Cancelled)